These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 32790958

  • 1. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
    Millar BC, McCaughan J, Rendall JC, Moore JE.
    Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
    [Abstract] [Full Text] [Related]

  • 2. In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.
    McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C, Cammarata S.
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [Abstract] [Full Text] [Related]

  • 3. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ, Liu HY, Lin YC, Sun KL, Chun CL, Hsueh PR.
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [Abstract] [Full Text] [Related]

  • 4. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC, Rendall JC, Downey DG, Moore JE.
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [Abstract] [Full Text] [Related]

  • 5. Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model.
    Craddock VD, Steere EL, Harman H, Britt NS.
    Antibiotics (Basel); 2023 Jun 20; 12(6):. PubMed ID: 37370396
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species.
    Kong Y, Li C, Li G, Yang T, Draz MS, Xie X, Zhang J, Ruan Z.
    Microbiol Spectr; 2022 Jun 29; 10(3):e0009922. PubMed ID: 35532225
    [Abstract] [Full Text] [Related]

  • 7. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2018 Nov 29; 62(11):. PubMed ID: 30104278
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility to delafloxacin of Pseudomonas aeruginosa with resistance to other quinolones (ciprofloxacin and levofloxacin).
    Jordán-Chaves JDD, Lobato-Cano R, Casas-Ciria J, Freyre-Carillo C, Santotoribio JD, de-la-Rubia-Martin MF.
    Clin Microbiol Infect; 2024 Mar 29; 30(3):405-406. PubMed ID: 38103637
    [No Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis.
    Ribeiro ÁCDS, Santos FF, Valiatti TB, Lenzi MH, Santos INM, Neves RFB, Moses IB, Meneses JP, Di Sessa RGG, Salles MJ, Gales AC.
    Braz J Infect Dis; 2024 Mar 29; 28(6):103867. PubMed ID: 39305936
    [Abstract] [Full Text] [Related]

  • 10. [In vitro activity of delafloxacin against bacterial isolates from osteoarticular and skin infections in Buenos Aires, Argentina].
    Nicola F, Azula N, Santoni G, Smayevsky J.
    Rev Argent Microbiol; 2022 Mar 29; 54(2):114-119. PubMed ID: 34053809
    [Abstract] [Full Text] [Related]

  • 11. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.
    Dostal RE, Seale JP, Yan BJ.
    Med J Aust; 1992 Jan 06; 156(1):20-4. PubMed ID: 1734188
    [Abstract] [Full Text] [Related]

  • 12. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.
    Zamorano L, Juan C, Fernández-Olmos A, Ge Y, Cantón R, Oliver A.
    Clin Microbiol Infect; 2010 Sep 06; 16(9):1482-7. PubMed ID: 20002107
    [Abstract] [Full Text] [Related]

  • 13. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA, Coates M, Thrane S, Sabnis A, Harrison J, Schelenz S, Edwards AM, Vorup-Jensen T, Davies JC.
    Microbiol Spectr; 2022 Aug 31; 10(4):e0081322. PubMed ID: 35727066
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
    Millar BC, Malnarcic CM, McCaughan J, Moore JE.
    Clin Respir J; 2020 Jan 31; 14(1):64-68. PubMed ID: 31663261
    [No Abstract] [Full Text] [Related]

  • 16. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP, Pandya AN, Karenchak LM, Romanowski EG, Husted RC, Ritterband DC, Shah MK, Gordon YJ.
    Ophthalmology; 2001 Oct 31; 108(10):1826-9. PubMed ID: 11581056
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM, Hamilton VE, Thomas MR.
    J Antimicrob Chemother; 1998 Aug 31; 42(2):171-8. PubMed ID: 9738834
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.